S&P/ASX 200 Index (ASX: XJO) shares are up 0.27% to 9,086.2 points as earnings season continues on Monday.
Among the 11 market sectors, materials and miners are in the lead today, up 1.7%.
The sector pushed higher amid BHP Group Ltd (ASX: BHP) shares reaching a new record of $67.72, up 3.9%, in early trading.
The financials sector is the laggard today, down 1%.
Let’s check out some new expert ratings on three ASX 200 sector heavyweights.
Pro Medicus Ltd (ASX: PME)
The Pro Medicus share price is $191.56, down 0.02% today and down 37% over 12 months.
Pro Medicus shares jumped 7.1% last week after the company released its FY26 results.
The Pro Medicus share price is up 20% since the downtrodden healthcare sector pivoted on 3 June.
Morgans maintained its accumulate rating on Pro Medicus shares after the report.
Analyst Iain Wilkie said:
FY26 confirms PME is executing at an even higher level than the market gave it credit for. EBIT margin of 74.9% and constant currency EBIT growth of 30.6% both beat expectations comfortably, with the FX-driven softness in headline revenue a currency story, not a demand or execution one.
Momentum remains broad-based, implementations are ahead of schedule, renewals are a clean sweep, and the pipeline is opening up in new segments rather than just deepening in existing ones.
Looking ahead, FY27 is shaping as a genuine standout year. With four Trinity cohorts and 15 other implementations already banked rather than still ramping, the P&L gets the full run-rate benefit without needing fresh signings just to stand still.
Nothing in the result gives us any pause for change versus our positive view.
Fortescue Ltd (ASX: FMG)
The Fortescue share price is $18.08, up 1.8% today and down 10% over 12 months.
Morgans has a hold rating on this ASX 200 mining share following the company’s FY26 report last week.
Analyst Adrian Prendergast said:
A mixed FY26 result from FMG, with higher revenue helping to offset cost increases and elevated admin/R&D to help keep underlying earnings flat.
With the focus on FY27 guidance, Iron Bridge remained a key issue, with the magnetite operation struggling through ramp up and with elevated costs.
Plans for a green steel plant was big news, although difficult to quantify.
Commonwealth Bank of Australia (ASX: CBA)
The CBA share price is $155.24, down 1.7% today and down 9% over 12 months.
CBA reported a 7% increase in its cash net profit after tax (NPAT) to $11 billion for FY26.
John Athanasiou from Red Leaf Securities has a sell rating on this ASX 200 bank share.
He explained (courtesy The Bull):
CBA shares deserves to trade at a premium given its dominant retail franchise, strong technology platform, solid deposit base and consistent execution.
However, Australian banking remains a mature industry, with intense competition across mortgages and deposits limiting the potential for outsized earnings growth.
At a premium valuation, investors are paying a higher price for quality, leaving little room for disappointment.
After a substantial re-rating, investors may be better served taking some profits and reallocating capital towards businesses offering stronger growth at more reasonable valuations.
The post Buy, hold, sell: Pro Medicus, Fortescue, CBA shares appeared first on The Motley Fool Australia.
Should you invest $1,000 in Pro Medicus right now?
Before you buy Pro Medicus shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Pro Medicus wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 1 August 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Are Westpac shares a buy at their new 52-week low?
- Experts name CBA and these ASX shares as sells today
- How much do you need invested in ASX dividend shares to replace a $90,000 salary?
- ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
- 5 things Warren Buffett looks for before buying ASX shares
Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended BHP Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.